Author Search Results :: UTM Library Massive Scholar Tracking

Suzanne L. Topalian

Suzanne Louise Topalian (born 1954) is an American surgical oncologist. She is the Bloomberg-Kimmel Professor of Cancer Immunotherapy in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine. In this role, she studies human anti-tumor immunity. Provided by Wikipedia

1

Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care by Drew M Pardoll, Suzanne L Topalian

Published 2025-01-01

Get full text

Article
2

Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR by Joeri L. Aerts, Monica I. Gonzales, Suzanne L. Topalian

Published 2004-01-01

Get full text

Article
3

Mechanisms regulating PD-L1 expression on tumor and immune cells by Shuming Chen, George A. Crabill, Theresa S. Pritchard, Tracee L. McMiller, Ping Wei, Drew M. Pardoll, Fan Pan, Suzanne L. Topalian

Published 2019-11-01

Get full text

Article
4

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy by Natalie J. Miller, Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, Shailender Bhatia, Lisa Lundgren, Martin A. Cheever, Suzanne L. Topalian, Paul Nghiem

Published 2018-11-01

Get full text

Article
5

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule by Jerome Galon, Sandra Demaria, Lisa H. Butterfield, Robert L. Ferris, Howard L. Kaufman, Willem W. Overwijk, Francesco M. Marincola, Pamela S. Ohashi, Ira Mellman, Pierre G. Coulie, Samir N. Khleif, Suzanne L. Topalian

Published 2016-11-01

Get full text

Article
6

Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy by Ke Xu, Qingfeng Zhu, Suzanne L Topalian, Robert A Anders, Janis M Taube, Mark Yarchoan, Keziban Ünsal-Kaçmaz, Logan L Engle, Tracee L McMiller, Sepideh Besharati, Junghwa Lee, Feriyl Bhaijee, Alan E Berger

Published 2024-11-01

Get full text

Article
7

Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: implications for immunotherapy by Amy S. Duffield, Maria Libera Ascierto, Robert A. Anders, Janis M. Taube, Alan K. Meeker, Shuming Chen, Tracee L. McMiller, Neil A. Phillips, Haiying Xu, Aleksandra Ogurtsova, Alan E. Berger, Drew M. Pardoll, Suzanne L. Topalian, Richard F. Ambinder

Published 2017-07-01

Get full text

Article
8

A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types by Zhen Zeng, Tianbei Zhang, Jiajia Zhang, Shuai Li, Sydney Connor, Boyang Zhang, Yimin Zhao, Jordan Wilson, Dipika Singh, Rima Kulikauskas, Candice D. Church, Thomas H. Pulliam, Saumya Jani, Paul Nghiem, Suzanne L. Topalian, Patrick M. Forde, Drew M. Pardoll, Hongkai Ji, Kellie N. Smith

Published 2025-02-01

Get full text

Article
9

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial by Bin Li, Jun Li, Tian Chen, Uwe M Martens, Lazar Vujanovic, Rom Leidner, Robert L Ferris, William Sharfman, Chrisann Kyi, Suzanne L Topalian, Janis M Taube, Christine H Chung, William C Spanos, Anthony Gonçalves, Lot A Devriese, Helene Gauthier, Simon I Chiosea, Julie E Stein, Adam Barrows

Published 2021-06-01

Get full text

Article
10

Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade by Shuming Chen, Tracee L. McMiller, Abha Soni, Farah Succaria, John-William Sidhom, Laura C. Cappelli, Livia A. Casciola-Rosen, Isaac R. Morales, Preethi Sankaran, Alan E. Berger, Julie Stein Deutsch, Qingfeng C. Zhu, Robert A. Anders, Jody E. Hooper, Drew M. Pardoll, Evan J. Lipson, Janis M. Taube, Suzanne L. Topalian

Published 2024-03-01

Get full text

Article
11

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab by Nicolas A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Benjamin Green, Abha Soni, Jonathan D. Cuda, Julie E. Stein, Joel C. Sunshine, Farah Succaria, Haiying Xu, Aleksandra Ogurtsova, Ludmila Danilova, Candice D. Church, Natalie J. Miller, Steve Fling, Lisa Lundgren, Nirasha Ramchurren, Jennifer H. Yearley, Evan J. Lipson, Mac Cheever, Robert A. Anders, Paul T. Nghiem, Suzanne L. Topalian, Janis M. Taube

Published 2018-10-01

Get full text

Article
12

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce by Mario Sznol, Roberta Zappasodi, Margaret K. Callahan, Dung T. Le, Robert L. Ferris, James L. Gulley, Charles G. Drake, Ryan J. Sullivan, Elad Sharon, Hussein A. Tawbi, Harriet M. Kluger, Janis M. Taube, Shilpa Gupta, Suzanne L. Topalian, Edward Cha, Michael A. Postow, Vassiliki A. Papadimitrakopoulou, Maria L. Ascierto, Michaela Bowden, Helen X. Chen, David M. Feltquate, Rachel W. Humphrey, Theresa M. LaVallee, Vanessa M. Hubbard-Lucey, Eric H. Rubin

Published 2020-05-01

Get full text

Article